As part of its advocacy program in the United States, ACRO submits regulatory comments to US regulators. This comment letter, submitted by ACRO to FDA in 2018 about Adaptive Designs for Clinical Trials of Drugs and Biologics can be found below.
As part of its advocacy program in the United States, ACRO submits regulatory comments to US regulators. This comment letter, submitted by ACRO to FDA in 2018 about Adaptive Designs for Clinical Trials of Drugs and Biologics can be found below.